Top

Discover Oncology

Published in:

Open Access 01-12-2024 | Prostate Cancer | Research

DSCAM-AS1 promotes the development of prostate cancer

Authors: Lin Cheng, Shuhui Li, Deqi Jiang, Jianchao Zhang

Published in: Discover Oncology | Issue 1/2024

Abstract

Purpose

The purpose of this study was to investigate the role of lncRNA DSCAM-AS1 in prostate cancer to find new therapeutic targets and promote the research progress of prostate cancer.

Methods

RT-qPCR was used to detect DSCAM-AS1 expression in prostate cancer tissues, normal tissues, human normal prostate epithelial cells (RWPE), and four prostate cancer cell lines. The clinical and prognostic role of DSCAM-AS1 was evaluated by the Kaplan–Meier curve and chi-square test. Secondly, a dual luciferase reporter gene assay was used to study the regulatory mechanism between miR-338-3p and DSCAM-AS1. Finally, the roles of DSCAM-AS1 and miR-338-3p in prostate cancer cell proliferation and metastasis were explored by CCK-8 and Transwell assays.

Results

It was found that DSCAM-AS1 upregulation could serve as a warning of deterioration and poor prognosis in prostate cancer patients, and that knockdown of DSCAM-AS1 expression inhibited the progression of prostate cancer cells. In addition, miR-338-3p, a target of DSCAM-AS1, was found to be down-regulated in prostate cancer cells and miR-338-3p knockdown could reverse the inhibitory effect of DSCAM-AS1 silencing on prostate cancer.

Conclusion

DSCAM-AS1 is up-regulated in prostate cancer and regulates the progression of prostate cancer cells by targeting miR-338-3p.

Available only for authorised users

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.CrossRefPubMed

Zhou J, Song Q, Liu X, Ye H, Wang Y, Zhang L, et al. lncRNA Erbb4-IR is downregulated in prostate carcinoma and predicts prognosis. Oncol Lett. 2020;19(5):3425–30. https://doi.org/10.3892/ol.2020.11464.CrossRefPubMedPubMedCentral

Chang AJ, Autio KA, Roach M 3rd, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014;11(6):308–23. https://doi.org/10.1038/nrclinonc.2014.68.CrossRefPubMedPubMedCentral

Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339(2):159–66. https://doi.org/10.1016/j.canlet.2013.06.013.CrossRefPubMed

Ulitsky I, Bartel DP. lincRNAs: genomics, evolution, and mechanisms. Cell. 2013;154(1):26–46. https://doi.org/10.1016/j.cell.2013.06.020.CrossRefPubMedPubMedCentral

Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, et al. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021;12(1):7349. https://doi.org/10.1038/s41467-021-26901-9.CrossRefPubMedPubMedCentral

Huang G, Guo X, Yang H. Long noncoding RNA SNHG1 promotes human prostate cancer progression by sponging miR-383-5p. Anticancer Drugs. 2021;32(3):286–95. https://doi.org/10.1097/cad.0000000000000916.CrossRefPubMed

You Z, Liu C, Wang C, Ling Z, Wang Y, Wang Y, et al. LncRNA CCAT1 promotes prostate cancer cell proliferation by interacting with DDX5 and MIR-28-5P. Mol Cancer Ther. 2019;18(12):2469–79. https://doi.org/10.1158/1535-7163.Mct-19-0095.CrossRefPubMed

Huang K, Tang Y. SChLAP1 promotes prostate cancer development through interacting with EZH2 to mediate promoter methylation modification of multiple miRNAs of chromosome 5 with a DNMT3a-feedback loop. Cell Death Dis. 2021;12(2):188. https://doi.org/10.1038/s41419-021-03455-8.CrossRefPubMedPubMedCentral

10.

Koo KM, Dey S, Trau M. A sample-to-targeted gene analysis biochip for nanofluidic manipulation of solid-phase circulating tumor nucleic acid amplification in liquid biopsies. ACS sensors. 2018;3(12):2597–603. https://doi.org/10.1021/acssensors.8b01011.CrossRefPubMed

11.

Mehra R, Udager AM, Ahearn TU, Cao X, Feng FY, Loda M, et al. Overexpression of the long non-coding RNA SChLAP1 independently predicts lethal prostate cancer. Eur Urol. 2016;70(4):549–52. https://doi.org/10.1016/j.eururo.2015.12.003.CrossRefPubMed

12.

Hu C. LncRNA DSCAM-AS1: a pivotal therapeutic target in cancer. Mini Rev Med Chem. 2023;23(5):530–6. https://doi.org/10.2174/1389557522666220822121935.CrossRefPubMed

13.

Yang Y, Cai J, Yang X, Wang K, Sun K, Yang Z, et al. Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma. Mol Thera J Am Soc Gene Thera. 2022;30(6):2342–53. https://doi.org/10.1016/j.ymthe.2022.02.021.CrossRef

14.

Tarighi M, Khalaj-Kondori M, Hosseinzadeh A, Abtin M. Long non-coding RNA (lncRNA) DSCAM-AS1 is upregulated in breast cancer. Breast Dis. 2021;40(2):63–8. https://doi.org/10.3233/BD-201010.CrossRefPubMed

15.

Li L, Chen P, Huang B, Cai P. lncRNA DSCAM-AS1 facilitates the progression of endometrial cancer via miR-136-5p. Oncol Lett. 2021;22(6):825. https://doi.org/10.3892/ol.2021.13086.CrossRefPubMedPubMedCentral

16.

Schatten H. Brief overview of prostate cancer statistics, grading, diagnosis and treatment strategies. Adv Exp Med Biol. 2018;1095:1–14. https://doi.org/10.1007/978-3-319-95693-0_1.CrossRefPubMed

17.

Wasim S, Lee SY, Kim J. Complexities of prostate cancer. Int J Mol Sci. 2022;23(22):14257. https://doi.org/10.3390/ijms232214257.CrossRefPubMedPubMedCentral

18.

Mitobe Y, Takayama KI, Horie-Inoue K, Inoue S. Prostate cancer-associated lncRNAs. Cancer Lett. 2018;418:159–66. https://doi.org/10.1016/j.canlet.2018.01.012.CrossRefPubMed

19.

Ghafouri-Fard S, Khoshbakht T, Taheri M, Ebrahimzadeh K. A review on the carcinogenic roles of DSCAM-AS1. Front Cell Dev Biol. 2021;9: 758513. https://doi.org/10.3389/fcell.2021.758513.CrossRefPubMedPubMedCentral

20.

C.-L. Yu N-WX, W. Jiang, H. Zhang, Y. MA. LncRNA DSCAM-AS1 promoted cell proliferation and invasion in osteosarcoma by sponging miR-101. 2020.

21.

Wang Y, Zhai S, Xing J, Zhang J, He Y, Wang G, et al. Long noncoding RNA DSCAM-AS1 facilitates proliferation and migration of hemangioma endothelial cells by targeting miR-411-5p/TPD52 axis. Biomed Res Int. 2022;2022:8696432. https://doi.org/10.1155/2022/8696432.CrossRefPubMedPubMedCentral

22.

Zhang H, Li S, Xu H, Sun L, Zhu Z, Yao Z. Interference of miR-107 with Atg12 is inhibited by HULC to promote metastasis of hepatocellular carcinoma. MedComm. 2020;1(2):165–77. https://doi.org/10.1002/mco2.25.CrossRefPubMedPubMedCentral

23.

Treeck O, Weber F, Fritsch J, Skrzypczak M, Schuler-Toprak S, Buechler C, et al. DSCAM-AS1 long non-coding RNA exerts oncogenic functions in endometrial adenocarcinoma via activation of a tumor-promoting transcriptome profile. Biomedicines. 2022;10(7):1727. https://doi.org/10.3390/biomedicines10071727.CrossRefPubMedPubMedCentral

24.

Jiang L, Hong L, Yang W, Zhao Y, Tan A, Li Y. Co-expression network analysis of the lncRNAs and mRNAs associated with cervical cancer progression. Arch Med Sci. 2019;15(3):754–64. https://doi.org/10.5114/aoms.2019.84740.CrossRefPubMedPubMedCentral

25.

Li C, Li X, Zhang Y, Wu L, He J, Jiang N, et al. DSCAM-AS1 promotes cervical carcinoma cell proliferation and invasion via sponging miR-338-3p. Environ Sci Pollut Res Int. 2022;29(39):58906–14. https://doi.org/10.1007/s11356-022-19962-w.CrossRefPubMed

26.

Degang JGH, Xuanhe Z, Tianhua Y, Jinghui Y. Long non-coding rna dscam-as1 accelerates the progression of hepatocellular.pdf. 2019.

27.

Wang Y, Qin H. miR-338-3p targets RAB23 and suppresses tumorigenicity of prostate cancer cells. Am J Cancer Res. 2018;8(12):2564–74.PubMedPubMedCentral

28.

Godtman RA, Kollberg KS, Pihl CG, Mansson M, Hugosson J. The association between age, prostate cancer risk, and higher gleason score in a long-term screening program: results from the goteborg-1 prostate cancer screening trial. Eur Urol. 2022;82(3):311–7. https://doi.org/10.1016/j.eururo.2022.01.018.CrossRefPubMed

Title: DSCAM-AS1 promotes the development of prostate cancer
Authors: Lin Cheng
Shuhui Li
Deqi Jiang
Jianchao Zhang
Publication date: 01-12-2024
Publisher: Springer US
Keywords: Prostate Cancer
Prostate Cancer
Metastasis
Published in: Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-024-00931-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

The prevalence of ADSL (rs3788579) and CYP1A2 (rs17861162) polymorphisms in female breast cancer patients in North-West Iran

Excluding external iliac node irradiation during neoadjuvant radiotherapy decreases lower intestinal toxicity without compromising efficacy in T4b rectal cancer patients with tumours involving the anterior structures

Fibrin glue mediated direct delivery of radiation sensitizers results in enhanced efficacy of radiation treatment

Prognostic significance of LINC01132 in lung cancer and its regulatory role in tumor progression

Elucidating the impact of parthanatos-related microRNAs on the tumoral immune microenvironment and clinical outcome in low-grade gliomas

GLUD1 inhibits hepatocellular carcinoma progression via ROS-mediated p38/JNK MAPK pathway activation and mitochondrial apoptosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials